Biology subjects

Gruss, A.

Publications and source records attributed to Gruss, A..

8 recordsLinked to original sources

bioRxiv2026

The fatty acid synthesis pathway is a checkpoint for lipoteichoic acid synthesis in Staphylococcus aureus

Bacterial membranes comprise diverse lipids whose proportions vary according to environmental conditions. How cells direct lipid flux toward specific products remains unclear. We address this question in the human pathogen Staphylococcus aureus, where multiple lipid products compete for a common precursor, the major phospholipid, phosphatidylglycerol (PG). One product, lipoteichoic acid (LTA), is essential for cell division, envelope homeostasis, and virulence. Lipids and metabolites were quantified to identify factors that prioritize LTA synthesis over the other PG-derived products. We identify upstream fatty acid synthesis (FASII) pathway as a key control point for LTA production. Inhibition of FASII by antibiotics or gene inactivation causes LTA depletion. FASII inhibition similarly affects LTA in Streptococcus agalactiae, suggesting conservation of this LTA control strategy. Changes in membrane fatty acids do not account for LTA depletion. Instead, we show that FASII inhibition causes a drop in intracellular glycerophosphate (GroP), a precursor for both PG and LTA. Under these conditions of GroP limitation, PG flux favors production of a non-GroP lipid, cardiolipin. Moreover, combined inhibition of FASII and WTA blocks S. aureus growth, confirming the lethality of depleting LTA and WTA simultaneously. This study resolves how S. aureus manages phospholipid flux, by prioritizing the synthesis of GroP-rich LTA or of non-GroP-containing lipids according to FASII-controlled GroP availability.

microbiology↗

bioRxiv2025

Biotope-dependent High Level Resistance to Reactive Oxygen Species, Antibiotic Tolerance, and Virulence of Staphylococcus aureus

The human and livestock pathogen Staphylococcus aureus poses a major clinical challenge due to antibiotic treatment failure. Its resilience is mainly attributed to antibiotic resistance and tolerance mechanisms related to persistence. Here we investigate how two infection-relevant biotopes, milk and serum, shape S. aureus pathogenic properties and capacity to withstand environmental stresses. Milk-versus serum-adapted bacteria show gross differences in envelope physical properties, membrane fatty acid composition and rigidity, and pigment production, and display distinct proteomic profiles. Compared to serum, milk adaptation of S. aureus confers extreme resistance to ROS damage, pronounced antimicrobial tolerance, and accelerated killing in an insect infection model. High level S. aureus pigmentation in whole milk is stimulated by milk lipids, and is responsible for high ROS resistance. The remarkable robustness of S. aureus in a milk biotope may signal the need to adjust antibiotic regimens when treating mastitis infections in humans and livestock.

microbiology↗

bioRxiv2024

Metabolic rerouting by gain-of-function mutations overcomes plsX essentiality in Staphylococcus aureus

Phospholipids are essential components of most cell membranes. In Staphylococcus aureus, PlsX acyltransferase is considered indispensable for initiating phospholipid synthesis, unless exogenous fatty acids (FAs) are available to bypass this requirement. We report that S. aureus can capture internal FA sources to overcome PlsX essentiality in a {Delta}plsX mutant via point mutations in either of two genes: fabF, which encodes the FA synthesis enzyme 3-oxoacyl-(acyl-carrier-protein) synthase II, or fadM, which encodes an understudied bifunctional acyl-CoA thioesterase and ACP binding protein. Despite growth rescue, both {Delta}plsX suppressors differ from the parental strain by producing phospholipids with shortened FA lengths suggesting that both suppressors lead to premature FA release during synthesis. Additionally, both suppressors display increased sensitivity to {beta}-lactam antibiotics. The similar behavior of both suppressors led us to show that fabF suppressors require the presence of fadM, indicative of FabF-FadM cooperation. We propose that reduced processivity of FabF suppressor variants, or greater availability of FadM for ACP binding in FadM variants, facilitates FA release from FabF-acyl-ACP intermediates. A FabF-FadM relay leading to FA release may contribute to homeostasis between FASII and phospholipid synthesis pathways. SignificancePhospholipids are vital cell membrane components. The essential Staphylococcus aureus phospholipid synthesis enzyme PlsX uses acyl-ACP, the end-product of fatty acid (FA) synthesis (FASII), to initiate phospholipid production. Despite its central role, PlsX can be substituted by exogenous FAs whose phosphorylation yields the same product. We discovered that without FA supplementation, mutants arise that rescue growth, indicating that internal FAs are released. Mutations occurred in either FabF, a FASII enzyme, or in FadM, an incompletely characterized protein. Our analyses give evidence that FabF and FadM proteins cooperate, and facilitate FA availability when either protein is mutated. We propose that in normal conditions, FadM might act as an "overflow valve" by releasing FAs from the FabF intermediate, which prevents buildup of FASII intermediates, and ensures FA-phospholipid balance. Remarkably, while this pathway rescues S. aureus growth, it sensitizes the MRSA strain to {beta}-lactam antibiotics.

microbiology↗

bioRxiv2023

The double-edged role of FASII regulator FabT in Streptococcus pyogenes infection

In Streptococcus pyogenes, the type II fatty acid (FA) synthesis pathway FASII is feedback- controlled by the FabT repressor bound to an acyl-Acyl carrier protein. Despite FabT defects being linked to reduced virulence in animal models, spontaneous fabT mutants arise in vivo. To resolve this paradox, we characterized the conditions and mechanisms that require FabT activity, and those that promote fabT mutant emergence. The primary fabT mutant defect is energy dissipation: specific nutrients are consumed, but the mutant fails to grow on human tissue, cells, or cell filtrates where nutrients are limited. These features explain the FabT requirement during infection. Conversely, fabT mutants exhibited a marked growth advantage over the wild-type in biotopes rich in saturated FAs. fabT mutants emerge in this context, where continued FASII activity prevented environmental FA incorporation. An ex vivo muscle model demonstrated that wild-type S. pyogenes was inhibited, while fabT mutant growth was stimulated, but conditional to FASII activity. Our findings elucidate the rationale for emerging fabT mutants that improve survival in lipid-rich biotopes, but lead to a genetic impasse for infection.

microbiology↗

bioRxiv2022

Inverse correlation between stress response and virulence factor expression in FASII antibiotic-adapted Staphylococcus aureus and consequences for infection

Antibiotics inhibiting the fatty acid synthesis (FASII) pathway of the major pathogen Staphylococcus aureus reach their enzyme targets, but bacteria continue growth by using environmental fatty acids (eFAs) to produce phospholipids. We assessed how extreme changes in membrane phospholipids provoked by FASII-antibiotics affect global S. aureus physiology. Anti-FASII provoked massive lasting expression changes without genomic rearrangements. Several regulators, rather than one master switch, contributed to the timing of anti-FASII adaptation. Numerous virulence and adhesion factors showed decreased levels and/or activity. Conversely, stress response protein levels increased, and correlated with greater tolerance to peroxides. Notably, peroxide priming stimulated eFA incorporation efficiency and facilitated adaptation to FASII inhibition. These findings establish a link between oxidative stress and FA incorporation. Consistent with major shift in protein expression, anti-FASII-adapted S. aureus killed an insect host more slowly but continued multiplying. Thus, while anti-FASII-adapted populations are less equipped to damage the host, they may be better fit for long term survival, and could constitute a reservoir for re-infection.

microbiology↗

bioRxiv2022

Staphylococcus aureus prophages are gatekeepers of exogenous lipid utilization to control membrane flexibility and bacterial fitness

Phages are ubiquitous in bacteria, including clinical Staphylococcus aureus, where Sfi 21/Sa3 phages often integrate into the hlb gene, encoding Hlb sphingomyelinase. The integration acts as a rapid regulatory switch of Hlb production. Our findings suggest that Sfi 21/Sa3 prophages and Hlb activity affect S. aureus fitness by modulating the incorporation of the toxic linoleic acid (C18:2) from serum into the bacterial membrane. This process relies on C18:2 derived from 1,3-diglyceride, facilitated by the FakB1 kinase subunit. Palmitic acid (C16), primarily released from serum through Hlb activity, competes for FakB1. This mechanism contributes to adaptation to AFN-1252, an antibiotic inhibiting the fatty acid synthesis pathway (anti-FASII). Since S. aureus relies on exogenous fatty acids for growth, AFN-1252 treatment leads to increased proportion of membrane C18:2. Moreover, Hlb inhibition, whether via prophage insertion, gene inactivation, or enzyme inhibition, delays S. aureus adaptation, resulting in higher proportionof C18:2 in the membrane. This study sheds light on the role of lipid environments in infections, and may contribute to the accurate prediction of infection risks and therapeutic efficacy. Furthermore, given that both anti-FASII and Hlb inhibitors enhance C18:2 incorporation, they represent potential agents for combined strategies against S. aureus.

microbiology↗

bioRxiv2020

(p)ppGpp and malonyl-CoA set the pace for Staphylococcus aureus adaptation to FASII antibiotics and provide a basis for bi-therapy inhibition

Fatty acid biosynthesis (FASII) enzymes are considered valid targets for antimicrobial drug development against the human pathogen Staphylococcus aureus. However, incorporation of host fatty acids confers FASII antibiotic adaptation that compromises prospective treatments. S. aureus adapts to FASII inhibitors by a first non-replicative latency period followed by outgrowth. Here we used transcriptional fusions and direct metabolite measurements to investigate the factors that dictate the duration of latency prior to outgrowth. We show that stringent response induction leads to repression of FASII and phospholipid synthesis genes. (p)ppGpp induction inhibits synthesis of malonyl-CoA, a molecule that derepresses FapR, a key regulator of FASII and phospholipid synthesis. Anti-FASII treatment also triggers transient expression of (p)ppGpp-regulated genes during the anti-FASII latency phase, with concomitant repression of FapR regulon expression. These effects are reversed upon outgrowth. GTP depletion, a known consequence of stringent response, also occurs during FASII latency, and is proposed as the common signal linking these responses. We next show that anti-FASII treatment shifts malonyl-CoA distribution between its interactants FapR and FabD, towards FapR, increasing expression of phospholipid synthesis genes plsX and plsC during outgrowth. We conclude that components of the stringent response dictate malonyl-CoA availability in S. aureus FASII regulation, and contribute to latency prior to anti-FASII-adapted outgrowth. A combinatory approach, coupling a (p)ppGpp inducer and an anti-FASII, blocks S. aureus outgrowth, opening perspectives for bi-therapy treatment. ImportanceStaphylococcus aureus is a major human bacterial pathogen for which new inhibitors are urgently needed. Antibiotic development has centered on the fatty acid synthesis (FASII) pathway, which provides the building blocks for bacterial membrane phospholipids. However, S. aureus overcomes FASII inhibition and adapts to anti-FASII by using exogenous fatty acids that are abundant in host environments. This adaptation mechanism comprises a transient latency period, followed by bacterial outgrowth. Here we use metabolite sensors and promoter reporters to show that responses to stringent conditions and to FASII inhibition intersect: both involve GTP and malonyl-CoA. These two signaling molecules contribute to modulating the duration of latency prior to S. aureus adaptation outgrowth. We exploit these novel findings to propose a bi-therapy treatment against staphylococcal infections.

microbiology↗

bioRxiv2019

Permissive Fatty Acid Incorporation in Host Environments Promotes Staphylococcal Adaptation to FASII Antibiotics

Development of fatty acid synthesis pathway (FASII) inhibitors against the major human pathogen Staphylococcus aureus hinges on the accepted but unproven postulate that an endogenously synthesized branched chain fatty acid is required to complete membrane phospholipids. Evidence for anti-FASII efficacy in animal models supported this view. However, restricted test conditions used previously to show FASII antibiotic efficacy led us to investigate these questions in a broader, host-relevant context. We report that S. aureus rapidly adapts to FASII antibiotics without FASII mutations when exposed to host environments. Treatment with a lead FASII antibiotic upon signs of infection, rather than just after inoculation as commonly practiced, failed to eliminate S. aureus from infected organs in a septicemia model. In vitro, addition of serum facilitated rapid S. aureus FASII bypass by environmental fatty acid (eFA) replacement in phospholipids. Serum lowers membrane stress, leading to increased retention of the two substrates required for exogenous fatty acid (eFA) utilization. In these conditions, eFA occupy both phospholipid positions 1 and 2, regardless of anti-FASII selection. This study revises conclusions on S. aureus fatty acid requirements by disproving the postulate of fatty acid stringency, and reveals an Achilles heel for using FASII antibiotics to treat infection in monotherapy.\n\nSignificance statementAntibiotic discovery to overcome treatment failure has huge socio-medical and economic stakes. The fatty acid synthesis (FASII) pathway is considered an ideal druggable target against the human pathogen Staphylococcus aureus, based on evidence of anti-FASII efficacy in infection models, and the postulate that S. aureus synthesizes an irreplaceable fatty acid. We report that S. aureus alters its behavior in host-relevant conditions. Administering FASII antibiotics upon signs of infection, rather than just after inoculation as frequently practiced, failed to clear septicemic infections. In serum, S. aureus rapidly overcomes FASII antibiotics by incorporating alternative fatty acids. We conclude that previously, premature antibiotic treatments and experimental constraints masked S. aureus antibiotic adaptation capacity. These findings should help streamline future drug development programs.

microbiology↗